Clinical Trial Update: Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study [Phase 2]

View source ↗

Summary

A Phase 2 double-blind clinical trial evaluating ICP-488 for efficacy and safety in subjects with Cutaneous lupus erythematosus; the study is not yet recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Lupus Erythematosus

Drugs mentioned

• ICP-488

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: Cutaneous Lupus Erythematosus (CLE) | Phase 2 | Status: NOT_YET_RECRUITING